October 16, 2024Offer of Employment • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations
On behalf of Jade Biosciences, Inc. (the “Company”), I am very pleased to offer you a position as General Counsel and Corporate Secretary of the Company (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below.
August 29, 2024 Jonathan Quick Re: Offer of Employment Dear Jonathan:Employment Agreement • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations
On behalf of Jade Biosciences, Inc. (the “Company”), I am very pleased to offer you a position as Senior Vice President, Finance of the Company (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below.
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CELL LINE LICENSE AGREEMENTCell Line License Agreement • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations
This Cell Line License Agreement (“Agreement”), effective as of October 22, 2024 (“EFFECTIVE DATE”), is entered and made by and between WuXi Biologics Ireland Limited, having an address at Dundalk Science & Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (collectively, “WuXi Biologics”) and Jade BioSciences, Inc., a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDMENT NO. 1 TO ANTIBODY DISCOVERY AND...Antibody Discovery and Option Agreement • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO ANTIBODY DISCOVERY AND OPTION AGREEMENT (this “Amendment”) is entered into and effective as of September 27, 2024 (the “Amendment Effective Date”), by and between Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parade Biosciences Holding, LLC, a Delaware limited liability company (“Parade”) and Jade Biosciences, Inc., a Delaware corporation (“Jade”), and amends that certain Antibody Discovery and Option Agreement, dated as of July 24, 2024, by and between Paragon, Parade and Jade (the “Option Agreement”). Paragon, Parade and Jade are also referred to herein individually as a “Party,” or collectively as the “Parties.”
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. ANTIBODY DISCOVERY AND OPTION AGREEMENTAntibody Discovery and Option Agreement • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
THIS ANTIBODY DISCOVERY AND OPTION AGREEMENT (“Agreement”) is entered into and effective as of July 24, 2024 (the “Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parade Biosciences Holding, LLC, a Delaware limited liability company (“Parade”) and Jade Biosciences, Inc., a Delaware corporation (“Jade”). Paragon, Parade and Jade are also referred to herein individually as a “Party”, or collectively as the “Parties.”
JADE BIOSCIENCES, INC. RESTRICTED STOCK NOTICERestricted Stock Purchase Agreement • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Jade Biosciences, Inc., a Delaware corporation (the “Company”), hereby grants to Purchaser (as defined below) the number of Shares (as defined below) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) set forth below, upon the terms and subject to the conditions set forth in the Restricted Stock Purchase Agreement attached hereto as Exhibit A (the “Restricted Stock Purchase Agreement”), which is incorporated by reference in this Restricted Stock Notice (the “Notice”). The issuance and sale of the Shares shall be effective as of the Date of Grant, set forth below.
LICENSE AGREEMENTLicense Agreement • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This License Agreement (“Agreement”) is entered into and effective as of October 30, 2024 (the “Effective Date”), by and between Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), and Jade Biosciences, Inc., a Delaware corporation (“Jade”). Paragon and Jade are also referred to herein individually as a “Party,” or collectively as the “Parties.”
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. BIOLOGICS MASTER SERVICES AGREEMENTBiologics Master Services Agreement • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations
This Biologics Master Services Agreement (this “Agreement”) is dated and effective as of July 3, 2024 (the “Effective Date”) and is between Jade BioSciences, Inc., a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Client”) and WuXi Biologics (Hong Kong) Limited, with its registered address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“Provider”), each of Client and Provider being a “Party,” and collectively the “Parties.”
August 20, 2024 Tom Frohlich Re: Offer of Employment Dear Tom:Offer of Employment • December 3rd, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations • British Columbia
On behalf of Jade Biosciences, Inc. (the “Company”), I am very pleased to offer you a position as Chief Executive Officer of the Company (“CEO”) and a member of the Company’s Board of Directors (the “Board”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below.
